|
Tabuľka |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Náklady na výnimkové lieky* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EMA OMP |
9 876 289 |
22,7% |
|
|
|
|
|
mil. € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VYN |
19 432 059 |
44,6% |
|
|
|
|
|
|
Podiel v 2020 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
|
CAGR |
|
|
|
|
AVASTIN |
4 240 432 |
9,7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Others |
9 975 626 |
22,9% |
|
|
|
|
|
EMA OMP |
23% |
9,352 |
8,944 |
9,398 |
9,489 |
9,876 |
13,200 |
14,400 |
15,500 |
16,800 |
18,400 |
|
13% |
|
|
|
|
|
|
|
|
|
|
|
|
In-label |
45% |
18,375 |
17,572 |
18,464 |
18,643 |
19,432 |
23,800 |
31,500 |
27,600 |
30,000 |
31,800 |
|
10% |
|
|
|
|
|
|
|
|
|
|
|
|
Avastin |
10% |
|
|
|
|
4,240 |
4,000 |
4,000 |
3,800 |
3,600 |
2,900 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Others |
23% |
|
|
|
|
9,976 |
10,000 |
10,000 |
10,000 |
10,000 |
9,600 |
|
|
|
|
|
|
In-label |
29 308 348 |
67,3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPOLU |
|
41,200 |
39,400 |
41,400 |
41,800 |
43,524 |
51,000 |
59,900 |
56,900 |
60,400 |
62,700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-4% |
5% |
1% |
|
17,2% |
17,5% |
-5,0% |
6,2% |
3,8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zdroj: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* ZP, MZ SR, odhad pre 2021-2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tabuľka |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Náklady na výnimkové lieky - dopad novely 363/2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
mil. € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EMA OMP |
23% |
9,352 |
8,944 |
9,398 |
9,489 |
9,876 |
13,200 |
14,400 |
11,000 |
6,900 |
1,400 |
|
-32% |
|
|
|
|
|
|
|
|
|
|
|
|
In-label |
45% |
18,375 |
17,572 |
18,464 |
18,643 |
19,432 |
23,800 |
32,600 |
12,300 |
6,000 |
2,000 |
|
-37% |
|
|
|
|
|
|
|
|
|
|
|
|
Avastin |
10% |
|
|
|
|
4,240 |
4,000 |
4,000 |
3,800 |
3,600 |
2,900 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Others |
23% |
|
|
|
|
9,976 |
10,000 |
10,000 |
10,000 |
10,000 |
9,600 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPOLU |
|
41,200 |
39,400 |
41,400 |
41,800 |
43,524 |
51,000 |
61,000 |
37,100 |
26,500 |
15,900 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-4% |
5% |
1% |
|
17,2% |
19,6% |
-39,2% |
-28,6% |
-40,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* ZP, MZ SR, odhad pre 2021-2025 |
|
|
|
|
|
|
|
1,100 |
-19,800 |
-33,900 |
-46,800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000 |
-13,900 |
-24,500 |
-35,100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,9% |
2,9% |
1,9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tabuľka |
|
|
|
|
|
|
|
|
50,700 |
38,280 |
25,080 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Úspory z režimu výnimkových liekov* |
|
|
|
|
|
|
1280 |
1300 |
1320 |
1320 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
mil. € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EMA OMP |
|
|
|
|
|
|
|
0,000 |
-4,500 |
-9,900 |
-17,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-label |
|
|
|
|
|
|
|
1,100 |
-15,300 |
-24,000 |
-29,800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Avastin |
|
|
|
|
|
|
|
0,000 |
0,000 |
0,000 |
0,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Others |
|
|
|
|
|
|
|
0,000 |
0,000 |
0,000 |
0,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPOLU |
|
|
|
|
|
|
|
1,100 |
-19,800 |
-33,900 |
-46,800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zdroj: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* ZP, MZ SR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|